ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1566129
This article is part of the Research TopicPrognostic Value of Inflammatory and Thrombotic Biomarkers in Acute Coronary SyndromeView all 4 articles
Correlation between serum cyclophilin A and acute ST-segment elevation myocardial infarction and its predictive value
Provisionally accepted
- 1The Second People's Hospital of Hefei, Hefei, China
- 2Bengbu Medical College, Bengbu, Anhui Province, China
- 3Anhui Provincial Hospital, Hefei, Anhui Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective Acute ST-segment elevation myocardial infarction (STEMI) is a serious cardiovascular event, and timely diagnosis and intervention are essential to improve prognosis. As a novel biomarker, serum cyclophilin A (CyPA) may play an important role in the development and progression of STEMI.Methods Two hundred and sixty-four patients with acute STEMI and 264 healthy controls were included in this study. The association of CyPA with STEMI was assessed by multivariate logistic regression analysis, and the potential value of CyPA in predicting STEMI risk was assessed using receiver operating characteristic curve (ROC) and reclassification analysis. In addition, calibration curves and decision curve analysis (DCA) were used to test the reliability of CyPA in predicting STEMI risk.Results The results showed that serum CyPA levels were significantly higher in patients with acute STEMI than in healthy controls (P < 0.001). Multivariate logistic regression analysis indicated that CyPA level was an independent risk factor for acute STEMI (OR = 1.15, 95% CI: 1.09, 1.23). In Model 3, each unit increase in CyPA was associated with a 17% increased risk of STEMI (P < 0.0001). Compared with Q1, the Q4 group (OR = 157.45, 95% CI: 65.19, 420.54) had a dramatically increased risk of STEMI. CyPA was found to have a non-linear relationship throughout the range by restricted cubic spline (RCS) analysis. The AUC of ROC curve analysis in model C was 0.994, which was significantly improved compared with model B (P = 0.01); the net reclassification index (NRI) was 0.0682 (P = 0.00029), and the comprehensive discriminant improvement index (IDI) was 0.0438 (P < 0.0001). The calibration curve showed that model C was more stable, and DCA showed that model C had better net yield, which was superior to model A and model B.Conclusion This study showed that serum cyclophilin A levels were closely associated with the development of acute ST-segment elevation myocardial infarction. CyPA may become a potential biomarker for acute STEMI.
Keywords: CyPA, Cyclophilin A, STEMI, ST-segment elevation myocardial infarction, prediction
Received: 24 Jan 2025; Accepted: 12 May 2025.
Copyright: © 2025 Wang, Wang, Fang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhenfei Chen, The Second People's Hospital of Hefei, Hefei, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.